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Profound reduction in tamoxifen active
metabolite endoxifen in a breast cancer
patient treated with rifampin prior to
initiation of an anti-TNFα biologic for
ulcerative colitis: a case report
Sara L. Henderson1,2, Wendy A. Teft1 and Richard B. Kim1*

Abstract
Background: Tamoxifen, a common anti-estrogen breast cancer medication, is a prodrug that undergoes
bioactivation via cytochrome P450 enzymes, CYP2D6 and to a lesser degree, CYP3A4 to form the active metabolite
endoxifen. With an increasing use of oral anti-cancer drugs, the risk for drug-drug interactions mediated by enzyme
inhibitors and inducers may also be expected to increase. Here we report the first case demonstrating a potent
drug-drug interaction in a real-world clinical setting between tamoxifen and rifampin in a breast cancer patient
being treated concurrently for ulcerative colitis.
Case presentation: We describe a patient on adjuvant tamoxifen therapy for breast cancer that was
prescribed rifampin for TB prophylaxis prior to initiation of an anti-tumor necrosis factor (TNF)-α agent due
to worsening ulcerative colitis. This 39 year old Caucasian woman had been followed by our personalized
medicine clinic where CYP2D6 genotyping and therapeutic monitoring of tamoxifen and endoxifen levels
had been carried out. The patient, known to be a CYP2D6 intermediate metabolizer, had a previous history
of therapeutic endoxifen levels. Upon admission to hospital for a major flare of her ulcerative colitis a
clinical decision was made to initiate an anti-TNFα biological agent. Due to concerns regarding latent TB,
rifampin as an anti-mycobacterial agent was initiated which the patient was only able tolerate for 10 days.
Interestingly, her plasma endoxifen concentration measured 2 weeks after cessation of rifampin was
sub-therapeutic at 15.8 nM and well below her previous endoxifen levels which exceeded 40 nM.
Conclusion: Rifampin should be avoided in patients on tamoxifen therapy for breast cancer unless
continued tamoxifen efficacy can be assured through endoxifen monitoring. Drug-drug interactions can
pose a significant risk of sub-therapeutic benefit in tamoxifen patients.
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Background
Tamoxifen is a selective estrogen receptor modulator
that is indicated as first-line and adjuvant treatment in
estrogen-receptor positive breast cancer. It has been
shown to decrease the risk of recurrence of breast cancer, as well as the risk of mortality [1]. Tamoxifen is a
prodrug that is extensively metabolized in the liver. The
efficacy of this drug is related to achieving therapeutic
plasma levels of both tamoxifen and its active metabolite
4-hydroxy-N-desmethyl-tamoxifen, otherwise known as
endoxifen [2]. Tamoxifen is converted to primary metabolites N-desmethyl-tamoxifen (NDM-tam) and 4-hydroxytamoxifen (4-OH-tam) which are both further converted
to endoxifen mainly by the cytochrome P450 (CYP) enzyme CYP2D6 and to a lesser extent by CYP3A4 [3]. It
has been well established that patients with CYP2D6
genetic deficiencies have lower endoxifen levels which
may place these patients at risk for being within a subtherapeutic range [4, 5]. Given the increasing use of oral
anticancer medications, like tamoxifen [6], the risk for
drug-drug interactions (DDI) mediated by enzyme inhibitors and inducers may also be expected to increase. Our
group has recently reported a DDI between the enzyme
inducer phenytoin and tamoxifen which resulted in profound reduction of endoxifen levels [7], indicating that
DDIs in addition to genetic deficiencies pose a real-world
risk for tamoxifen patients.
As CYP3A4 plays a role in converting tamoxifen to
endoxifen, it was thought that CYP3A4 induction by
drugs such as rifampin may result in increased endoxifen
levels, thus mitigating the low levels often seen among
patients with CYP2D6 deficiencies. A recent pharmacokinetic study designed to test this hypothesis was prematurely stopped when the first four subjects had a marked
decrease in endoxifen levels after rifampin administration [8]. Here, we present to our knowledge the first case
report demonstrating a potent DDI in a real-world clinical
setting where a patient was being treated concurrently
with rifampin while on tamoxifen therapy. While oral
anticancer agents are likely associated with improved
quality of life and convenient for oncology patients [9],
clinically relevant DDIs may have a significant impact on
the efficacy of tamoxifen treatment.
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dose of 20 mg daily. The patient provided written informed consent for participation in our approved study
allowing for pharmacogenetic testing of CYP2D6 and
drug level analysis of tamoxifen and endoxifen levels
using an established liquid chromatography-tandem
mass spectrometry method [5]. Other medical history included a 12-year history of ulcerative colitis and occasional migraine headaches. In addition to tamoxifen, her
medications at this time included ascorbic acid, ferrous
gluconate, and 5-aminosalicylic acid. Results of CYP2D6
genotyping revealed a genotype of *1/*4, indicating that
she was an intermediate metabolizer. The tamoxifen level
of the patient was 313.29 nM and the endoxifen level was
42.89 nM, considered to be well within therapeutic range
(Fig. 1a, Table 1, Additional file 1). Although she did report complaints of hot flashes and moodiness, she was
otherwise able to tolerate tamoxifen. A follow-up visit in
November 2013 to our clinic again revealed tamoxifen
and endoxifen levels within therapeutic range.

Case presentation
Relevant medical history

In April 2013, a 38-year-old woman was referred to our
Personalized Medicine Tamoxifen Clinic for assessment.
One year previously she had been diagnosed with rightbreast invasive carcinoma, stage T1cN0M0, estrogen/
progesterone receptor positive, human epidermal growth
factor receptor 2/neu negative, and underwent right
segmental mastectomy and subsequent radiation. In
January 2013, she was started on adjuvant tamoxifen at a

Fig. 1 Plasma levels of tamoxifen and metabolites before and
after rifampin administration. Blood samples were obtained prior
to rifampin treatment with baseline collected right before
rifampin initiation. Follow-up samples were collected 2 and
10 weeks post-rifampin discontinuation. Plasma concentrations of
tamoxifen and endoxifen (a) and primary metabolites, NDM-tamoxifen
and 4-OH-tamoxifen (b) were measured from each blood sample.
Horizontal shaded region in (a) depicts the sub-therapeutic
range. Vertical shaded region in (a) and (b) depicts the time
period of rifampin treatment
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Table 1 Drug levels and metabolite/parent ratios before and after rifampin administration
Blood sample
Baseline

2-weeks post rifampin

10-weeks post rifampin

Tamoxifen

225.25

171.18 (24.0)

259.12 (0.0)

NDM-tam

386.32

177.38 (54.1)

365.66 (5.4)

Analyte, nM (%)a

4-OH-tam

6.41

2.67 (58.3)

4.29 (33.0)

Endoxifen

46.03

15.75 (65.8)

29.45 (36.0)

NDM-tam/tamoxifen

1.715

1.036 (39.6)

1.411 (17.8)

Metabolite/Parent ratio (%)a

4-OH-tam/tamoxifen

0.028

0.016 (45.1)

0.017 (41.8)

endoxifen/tamoxifen

0.204

0.092 (55.0)

0.114 (44.4)

endoxifen/NDM-tam

0.119

0.089 (25.5)

0.081 (32.4)

endoxifen/4-OH-tam

7.185

5.892 (18.0)

6.862 (4.5)

a

% reduction from baseline measurement

Clinical consult for ulcerative colitis flare

In July 2014, this patient suffered a flare of her ulcerative colitis and was admitted to hospital for management. The patient tested positive for latent tuberculosis
during TB skin testing routinely performed prior to
anti-TNFα monoclonal antibody treatment. As a result,
she was to be started on 4 months of preventative
tuberculosis therapy with rifampin. Our team was then
asked to see her for assessment of a potential drug
interaction between rifampin and tamoxifen. Other
medications at this time included ascorbic acid, vitamin
D, dalteparin, ferrous gluconate, and methylprednisolone. Repeat baseline tamoxifen and endoxifen levels
were measured, and were consistent with previous
testing (tamoxifen 225.25 nM, endoxifen 46.03 nM).
Upon initiation of rifampin we anticipated a reduction
of endoxifen due to the previous clinical study by
Binkhorst et al, but predicted this patient would remain
in therapeutic range based on her baseline endoxifen
levels. She was discharged several days later with a
prescription for rifampin 600 mg daily for 4 months
but was only able to tolerate rifampin for 10 days. She
was then re-admitted to hospital due to worsening
ulcerative colitis and the rifampin was discontinued.
Two weeks later, we obtained a blood sample for repeat
tamoxifen and endoxifen levels. The tamoxifen level
was 171.18 nM, approximately 24 % lower than baseline; while the endoxifen level was reduced by 66 % to
15.75 nM (Fig. 1a). The decreased level of endoxifen
was not due to the lower tamoxifen level as the endoxifen/tamoxifen ratio was 55 % lower following rifampin
treatment (0.09) compared to the baseline ratio (0.2)
(Table 1). At 10 weeks post discontinuation of rifampin,
measured endoxifen level had nearly doubled at 29.45
nM (Fig. 1a, Table 1), placing the patient back within
therapeutic range.

In addition to tamoxifen and endoxifen levels, we measured primary metabolites NDM-tam and 4-OH-tam from
each blood sample (Fig. 1b). We observed a greater than
50 % reduction of NDM-tam and 4-OH tam levels
following rifampin treatment. A similar rebound effect of
primary metabolites was observed at 10 weeks postdiscontinuation of rifampin. While a reduction in the metabolite/parent ratios was observed at each conversion
step in the tamoxifen to endoxifen pathway (Table 1), the
most significant ratio reduction was noted for NDM-tam/
tamoxifen and 4-OH-tam/tamoxifen (40 and 45 % reduction, respectively) suggesting the conversion of tamoxifen
to either primary metabolite was rate limiting to the
formation of endoxifen (Table 1).

Discussion
Tamoxifen undergoes oxidative biotransformation to its
metabolites primarily by the CYP enzymes CYP3A4 and
CYP2D6. In particular, endoxifen formation, the main
active metabolite thought to be responsible for tamoxifen’s therapeutic effect, is catalyzed by the CYP2D6
enzyme [4, 10]. It was therefore traditionally hypothesized that the concurrent use of potent CYP3A4 inducers, such as rifampin, may increase the amount of
endoxifen formed, and in fact have a beneficial effect on
the clinical outcomes of tamoxifen users, particularly
among CYP2D6 poor metabolizers (PM). The effect of
potent inducers such as rifampin can be multifactorial.
We have shown that nuclear receptors such as Pregnane
X Receptor (PXR) and Hepatocyte Nuclear Receptor 4α
(HNF4α) regulate CYP3A4 expression [11]. Therefore,
in principle, activation of PXR would be predicted to
increase the level of endoxifen. However, we now know
that endoxifen clearance may be further enhanced through
the action of phase II enzymes as well as drug transporters.
Indeed, our group has shown that endoxifen is an excellent
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substrate for P-glycoprotein and that central nervous
system entry of endoxifen was nearly 20-fold greater
in P-glycoprotein deficient mice, due to its absence at
the blood brain barrier [12]. P-glycoprotein is also
highly expressed in the apical domain of enterocytes
thus reducing substrate drug absorption, while its
expression on the canalicular domain of hepatocytes
facilitates biliary excretion [13]. In addition, induction
of glucuronidation is also likely involved in the enhanced
clearance of tamoxifen and its metabolites [14]. Rifampin
has been shown to induce several conjugating enzymes,
including the uridine 5’-diphospho-glucuronosyltransferase (UGT) enzyme that catalyzes glucuronidation [15]. An
interaction between rifampin and tamoxifen was noted in
the late 1990s when a study showed a marked reduction
in tamoxifen levels [16]. However, in terms of clinical
impact, only recently have reports demonstrated drugs
such as phenytoin and rifampin may have a deleterious
effect on endoxifen formation [7, 8]. Based on the previous hypothesis that concurrent use of rifampin and
tamoxifen would enhance endoxifen levels, the clinical
trial published by Binkhorst et al was designed to show a
beneficial effect among breast cancer patients on tamoxifen therapy [8]. However, the investigators terminated the
study prematurely due to interim analysis data that
showed profound reduction in endoxifen levels.
Here, we had the opportunity to investigate a potential
DDI in a patient requiring both tamoxifen and rifampin.
Through measurement of tamoxifen and metabolite levels
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prior to and following rifampin administration we were
able to clearly document the reduction in metabolite
formation. As the bioactivation of tamoxifen is complex,
involving multiple drug metabolizing enzymes and
transporters for metabolite clearance, we suggest that
rifampin induction may play a role in multiple, nonmutually exclusive pathways resulting in lower systemic
exposure of endoxifen. Induction of phase II enzymes
and P-glycoprotein may result in increased clearance of
endoxifen (Fig. 2). Additionally, the large reduction in
the ratio of either primary metabolite to tamoxifen
suggests that tamoxifen may in fact be metabolized to
an alternate metabolite, reducing the formation of
NDM-tam and 4-OH-tam, which are necessary for
endoxifen formation (Fig. 2). It is important to note
that the absorption and bioavailability of many drugs
may be affected in the setting of inflammatory bowel
disease. However, here we were able to measure the
ratio of endoxifen to tamoxifen at several time points
during the UC flare, including just prior to rifampin
initiation (considered as baseline) and two weeks post
rifampin discontinuation. The profound reduction in
the endoxifen/tamoxifen ratio following rifampin treatment suggests that endoxifen is being cleared more
rapidly than at baseline. Therefore, although we can’t rule
out altered gut absorption, we predict this effect is primarily due to the drug interaction and not the disease setting.
Rifampin is used in the treatment of a number of infections, including those caused by tuberculous or non-

Fig. 2 Proposed pathways induced by rifampin resulting in decreased endoxifen levels. Tamoxifen is bioactivated by CYP enzymes to form
primary metabolites, NDM-tamoxifen and 4-OH-tamoxifen which are both further converted to the active metabolite endoxifen. Rifampin may
lead to the marked reduction in endoxifen levels by (a) shunting tamoxifen metabolism to form alternate metabolites or (b) inducing phase II
conjugating enzymes or drug transporters, such as P-glycoprotein, resulting in increased clearance of endoxifen

Henderson et al. BMC Cancer (2016) 16:304

tuberculous mycobacterium, and methicillin-susceptible
or methicillin-resistant staphylococci. This broad spectrum
of coverage likely means that its use remains consistent,
particularly in the setting of a large, tertiary hospital site.
Additionally, the use of tamoxifen is widespread in
those who have received a diagnosis of breast cancer,
as well as for specific populations of women at highrisk for cancer. Therefore, it is likely that a significant
number of patients may be receiving concurrent therapy with both agents. We are struck by the magnitude of the inductive effect of rifampin on tamoxifen
metabolism. A near 3-fold reduction in endoxifen
level after only 10 days of rifampin therapy would
suggest most patients on such combinations would be
predicted to lose therapeutic benefit from tamoxifen
placing them at a higher risk of recurrence.

Conclusion
To our knowledge, this is the first case report in a realworld clinical setting that documents the profound effect
of rifampin on endoxifen level. Importantly, we provide
tamoxifen and endoxifen levels before and after rifampin
therapy that clearly demonstrate the deleterious effect of
rifampin to tamoxifen therapy. We believe that patients
taking both tamoxifen and rifampin are at an increased
risk for breast cancer recurrence or incidence, which
may be of particular concern among high-risk patients,
and should be avoided when possible. If it is essential
that both agents be used, this case also highlights the
importance of therapeutic drug monitoring of tamoxifen
and endoxifen to optimize therapy.
Ethics consent

Written informed consent was obtained from the patient
for measuring drug levels and pharmacogenetic testing
as approved by the Research Ethics Board, the University
of Western Ontario (REB 15586).
Consent to publish

Written informed consent was obtained from the patient for publication of this Case report. A copy of the
written consent is available for review by the Editor of
this journal.
Availability of data and materials

The datasets supporting the conclusions of this article are included within the article (and its additional
files).
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metabolite/parent ratios for tamoxifen and its metabolites. (XLSX 10 kb)
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